

Figure S4-1

CONTROL






Figure S4-2

FAK inactivation with PF573528, 1 μ M





Figure S4-3

ERK1 inactivation with PD98059, 2 μ M





Figure S4-4

Src inactivation with SU6656, 5 μ M






Figure S4-5

JNK inactivation with SP600125, 1,8 μ M






Figure S4-6

ROCK inactivation with Y27632, 5 μ M






Figure S4-7

Myosin II inactivation with Blebbistatin, 15 μ M






Figure S4-8

MLCK inactivation with ML7, 5 μ M





Figure S4-9

Rac inactivation with NCS23766, 5 μ M





Figure S4-10

laminin on micropattern





Figure S4-11

siRNA against GFP (si RNA control)





Figure S4-12

siRNA against p120-catenin

